Edition:
India

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

20.48USD
20 Jul 2018
Change (% chg)

$0.05 (+0.24%)
Prev Close
$20.43
Open
$20.40
Day's High
$20.51
Day's Low
$20.19
Volume
49,075
Avg. Vol
92,950
52-wk High
$30.06
52-wk Low
$16.24

Select another date:

Wed, May 9 2018

BRIEF-Aclaris Therapeutics Q1 Loss Per Share $0.98

* ACLARIS THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS

BRIEF-Aclaris Therapeutics Announces Availability Of Eskata In The U.S.

* ACLARIS THERAPEUTICS ANNOUNCES AVAILABILITY OF ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W)

BRIEF-Aclaris Therapeutics Names Bryan Reasons Director And Chairman, Audit Committee

* ACLARIS THERAPEUTICS ANNOUNCES APPOINTMENT OF BRYAN REASONS AS A DIRECTOR AND CHAIRMAN OF THE AUDIT COMMITTEE Source text for Eikon: Further company coverage:

BRIEF-Aclaris Says Primary, Secondary, And Exploratory Endpoints Of Phase 2 Trial of A-101 45% Met

* ACLARIS THERAPEUTICS ANNOUNCES POSITIVE UPDATE ON PHASE 2 RESULTS AFTER A 3-MONTH FOLLOW-UP OF A-101 45% TOPICAL SOLUTION FOR POTENTIAL TREATMENT OF COMMON WARTS

BRIEF-Aclaris Therapeutics Q4 Revenue $1.0 Mln

* ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS

BRIEF-Aclaris Therapeutics Issues U.S. Patent Covering JAK Inhibitor For Treating Hair Loss Disorders

* ACLARIS THERAPEUTICS ANNOUNCES ISSUANCE OF U.S. PATENT COVERING A JAK INHIBITOR FOR TREATING HAIR LOSS DISORDERS Source text for Eikon: Further company coverage:

BRIEF-Aclaris Therapeutics Signs Agreement With James Alexander Corp

* ACLARIS THERAPEUTICS SAYS ON JAN 24, CO ENTERED INTO COMMERCIAL SUPPLY MANUFACTURING SERVICES AGREEMENT WITH JAMES ALEXANDER CORP - SEC FILING

Select another date: